556 related articles for article (PubMed ID: 18559090)
1. The CD44+/CD24- phenotype is enriched in basal-like breast tumors.
Honeth G; Bendahl PO; Ringnér M; Saal LH; Gruvberger-Saal SK; Lövgren K; Grabau D; Fernö M; Borg A; Hegardt C
Breast Cancer Res; 2008; 10(3):R53. PubMed ID: 18559090
[TBL] [Abstract][Full Text] [Related]
2. A CD44⁻/CD24⁺ phenotype is a poor prognostic marker in early invasive breast cancer.
Ahmed MA; Aleskandarany MA; Rakha EA; Moustafa RZ; Benhasouna A; Nolan C; Green AR; Ilyas M; Ellis IO
Breast Cancer Res Treat; 2012 Jun; 133(3):979-95. PubMed ID: 22119938
[TBL] [Abstract][Full Text] [Related]
3. Association of CD44
Chekhun VF; Lukianova NY; Chekhun SV; Bezdieniezhnykh NO; Zadvorniy TV; Borikun TV; Polishchuk LZ; Klyusov OМ
Exp Oncol; 2017 Sep; 39(3):203-211. PubMed ID: 28967645
[TBL] [Abstract][Full Text] [Related]
4. CD44/CD24 as potential prognostic markers in node-positive invasive ductal breast cancer patients treated with adjuvant chemotherapy.
Adamczyk A; Niemiec JA; Ambicka A; Mucha-Małecka A; Mituś J; Ryś J
J Mol Histol; 2014 Feb; 45(1):35-45. PubMed ID: 23835592
[TBL] [Abstract][Full Text] [Related]
5. Distinct patterns of promoter CpG island methylation of breast cancer subtypes are associated with stem cell phenotypes.
Park SY; Kwon HJ; Choi Y; Lee HE; Kim SW; Kim JH; Kim IA; Jung N; Cho NY; Kang GH
Mod Pathol; 2012 Feb; 25(2):185-96. PubMed ID: 22037257
[TBL] [Abstract][Full Text] [Related]
6. CD44+/CD24- phenotype contributes to malignant relapse following surgical resection and chemotherapy in patients with invasive ductal carcinoma.
Lin Y; Zhong Y; Guan H; Zhang X; Sun Q
J Exp Clin Cancer Res; 2012 Jul; 31(1):59. PubMed ID: 22762532
[TBL] [Abstract][Full Text] [Related]
7. Functional heterogeneity within the CD44 high human breast cancer stem cell-like compartment reveals a gene signature predictive of distant metastasis.
Leth-Larsen R; Terp MG; Christensen AG; Elias D; Kühlwein T; Jensen ON; Petersen OW; Ditzel HJ
Mol Med; 2012 Sep; 18(1):1109-21. PubMed ID: 22692575
[TBL] [Abstract][Full Text] [Related]
8. SLUG/SNAI2 and tumor necrosis factor generate breast cells with CD44+/CD24- phenotype.
Bhat-Nakshatri P; Appaiah H; Ballas C; Pick-Franke P; Goulet R; Badve S; Srour EF; Nakshatri H
BMC Cancer; 2010 Aug; 10():411. PubMed ID: 20691079
[TBL] [Abstract][Full Text] [Related]
9. Effect of curcumin on the cell surface markers CD44 and CD24 in breast cancer.
Calaf GM; Ponce-Cusi R; Abarca-Quinones J
Oncol Rep; 2018 Jun; 39(6):2741-2748. PubMed ID: 29693159
[TBL] [Abstract][Full Text] [Related]
10. The CD44+/CD24- phenotype relates to 'triple-negative' state and unfavorable prognosis in breast cancer patients.
Giatromanolaki A; Sivridis E; Fiska A; Koukourakis MI
Med Oncol; 2011 Sep; 28(3):745-52. PubMed ID: 20405247
[TBL] [Abstract][Full Text] [Related]
11. The role of CD44+/CD24-/low biomarker for screening, diagnosis and monitoring of breast cancer.
Camerlingo R; Ferraro GA; De Francesco F; Romano M; Nicoletti G; Di Bonito M; Rinaldo M; D'Andrea F; Pirozzi G
Oncol Rep; 2014 Mar; 31(3):1127-32. PubMed ID: 24366074
[TBL] [Abstract][Full Text] [Related]
12. Tumor-endothelial interaction links the CD44(+)/CD24(-) phenotype with poor prognosis in early-stage breast cancer.
Buess M; Rajski M; Vogel-Durrer BM; Herrmann R; Rochlitz C
Neoplasia; 2009 Oct; 11(10):987-1002. PubMed ID: 19794958
[TBL] [Abstract][Full Text] [Related]
13. Metalloprotease-dependent activation of EGFR modulates CD44
Wise R; Zolkiewska A
Breast Cancer Res Treat; 2017 Nov; 166(2):421-433. PubMed ID: 28791489
[TBL] [Abstract][Full Text] [Related]
14. Clinical-pathologic significance of cancer stem cell marker expression in familial breast cancers.
Bane A; Viloria-Petit A; Pinnaduwage D; Mulligan AM; O'Malley FP; Andrulis IL
Breast Cancer Res Treat; 2013 Jul; 140(1):195-205. PubMed ID: 23813303
[TBL] [Abstract][Full Text] [Related]
15. ALDH1 is a better clinical indicator for relapse of invasive ductal breast cancer than the CD44+/CD24- phenotype.
Zhong Y; Shen S; Zhou Y; Mao F; Guan J; Lin Y; Xu Y; Sun Q
Med Oncol; 2014 Mar; 31(3):864. PubMed ID: 24519209
[TBL] [Abstract][Full Text] [Related]
16. Phenotypic characterization of mammosphere-forming cells from the human MA-11 breast carcinoma cell line.
Rappa G; Lorico A
Exp Cell Res; 2010 May; 316(9):1576-86. PubMed ID: 20074564
[TBL] [Abstract][Full Text] [Related]
17. Are CD44
Ryspayeva DE; Smolanka II; Dudnichenko АS; Lyashenko AA; Grinevich YA; Gurianov VG; Koshubarova MV; Seleznev AA
Exp Oncol; 2017 Sep; 39(3):224-228. PubMed ID: 28967636
[TBL] [Abstract][Full Text] [Related]
18. BRCA1-IRIS overexpression promotes and maintains the tumor initiating phenotype: implications for triple negative breast cancer early lesions.
Sinha A; Paul BT; Sullivan LM; Sims H; El Bastawisy A; Yousef HF; Zekri AN; Bahnassy AA; ElShamy WM
Oncotarget; 2017 Feb; 8(6):10114-10135. PubMed ID: 28052035
[TBL] [Abstract][Full Text] [Related]
19. CD44 isoforms are heterogeneously expressed in breast cancer and correlate with tumor subtypes and cancer stem cell markers.
Olsson E; Honeth G; Bendahl PO; Saal LH; Gruvberger-Saal S; Ringnér M; Vallon-Christersson J; Jönsson G; Holm K; Lövgren K; Fernö M; Grabau D; Borg A; Hegardt C
BMC Cancer; 2011 Sep; 11():418. PubMed ID: 21957977
[TBL] [Abstract][Full Text] [Related]
20. Breast cancer stem cells and intrinsic subtypes: controversies rage on.
Nakshatri H; Srour EF; Badve S
Curr Stem Cell Res Ther; 2009 Jan; 4(1):50-60. PubMed ID: 19149630
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
